Navigation Links
PDC Biotech GmbH Announces Close of Series A Financing
Date:10/31/2009

ig.ag
MIG AG is a Munich-based venture capital firm with an investment focus on early to mid-stage life science and technology companies in German-speaking Europe. As one of Germany's most active venture capital firms, MIG AG has invested in over twenty innovative companies in Austria and Germany. Based in Munich, the company initiates and manages venture capital funds with a volume exceeding 300 million.


For more information, please contact
PDC Biotech GmbH
Diane Kalina +43 (1)8900077-20
dkalina@pdcbiotech.com


'/>"/>
b3c newswire

Page: 1 2 3

Related biology news :

1. Media source impacts ag biotech communication
2. KINAXO Biotechnologies and Bayer Vital GmbH Collaborate in Phosphoproteomics Biomarker Identification
3. GATC Biotech AG is investing more than 5 million euros in its Constance site to double the companys floor space
4. Anti-biotech groups obstruct forest biotechnology
5. GenWay Biotech obtains exclusive rights to AMDLs DR-70 cancer test in US and Canada
6. Genome sequencing of fungus with biotechnological applications
7. Biotech scientists team with curators to stem decay of worlds art, cultural heritage
8. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. CU-Boulder, biotech firm team up on python project in search for human cardiac therapeutics
11. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... RESEARCH TRIANGLE PARK, North Carolina , ... in sein 35. Jahr als spezialisiertes Logistikunternehmen ... seine Position als einzige klinische Logistikfirma (Clinical ... soll. Die Kernbotschaft der neuen Kampagne lautet ... Protokollen und Lieferungen. Foto: ...
(Date:2/5/2015)... , Jan. 27, 2015   Marvin ... globally deployed, innovative test solutions for military, ... delivery of its TS-323 GENASYS Test ... Company (LMSSC). GENASYS is a high-performance PXI-based ... mission-critical applications that require performance functional testing. ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying to ... and potential for genomic science as a means to ... prevention and treatment.  I was honored to participate in ... precision medicine program. Since the 1980s ... of genomics—from the first sequenced genome of a free ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2
... drug-resistant infections are the result of bacterial biofilms, structured ... are extremely resistant to environmental stresses. These biofilms impact ... example, is a disease in which patients die from ... the most potent antibiotics. Now, UCLA ...
... reported in today,s issue of the journal Science ... produce insect-killing proteins isolated from the soil bacterium ... to neighboring farmers who grow non-transgenic varieties of corn. ... a critical role in addressing many of the toughest ...
... about a walk on the wild side: University of ... new paper that shows that bacteria are capable of ... of civil engineering and geological sciences and a member ... studying the surface motility of bacteria since 2004. In ...
Cached Biology News:UCLA-led research team finds that bacteria can stand up and walk 2UCLA-led research team finds that bacteria can stand up and walk 3New study shows benefits of Bt corn to farmers 2Notre Dame researcher helps discover 'walking' properties of bacteria 2
(Date:2/26/2015)... (PRWEB) February 26, 2015 On Wednesday, ... to building a nationwide Clostridium difficile (C. diff) awareness ... diff burden study by the Centers for Disease Control ... caused almost half a million infections among Americans in ... nursing homes. , The study also estimates that ...
(Date:2/25/2015)... 25, 2015 /CNW/ - Radient Technologies Inc. (TSX-V: RTI) (the ... results for the third quarter of its fiscal year ... Discussion and Analysis, and the CEO & CFO certifications ... 31, 2014 are available on www.SEDAR.com ... The Corporation is also pleased to announce the appointment ...
(Date:2/25/2015)... HONG KONG, Feb. 25, 2015 China Cord ... the "Company"), China,s leading provider of cord blood collection, ... storage services, today announced its preliminary unaudited financial results ... fiscal 2015 ended December 31, 2014. Third ... the third quarter of fiscal 2015 increased by 10.7% ...
(Date:2/25/2015)... (PRWEB) February 25, 2015 AnthroTronix ... firm committed to optimizing the interaction between people ... a 2015 Award Finalist by the internationally renowned ... DANA™. DANA™ can provide health professionals data within ... of brain injury and can provide baseline data ...
Breaking Biology Technology:Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4Radient Technologies Inc. Releases Third Quarter Results and Appoints New Interim CFO 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 2China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 3China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 4China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 5China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 6China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 7China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 8China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 9China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 10China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 11China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 12China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 13China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 14China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 15China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 16China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 17China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 18China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 19China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 20China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 21China Cord Blood Corporation Reports Financial Results for the Third Quarter and First Nine Months of Fiscal 2015 22AnthroTronix Named Edison Awards Finalist for Brain Health Assessment Tool 2AnthroTronix Named Edison Awards Finalist for Brain Health Assessment Tool 3
... Inc. (Nasdaq: MDVN) today announced that it will hold a ... to discuss partnering plans for MDV3100, Medivation,s investigational drug which ... prostate cancer. , Teleconference/Webcast Details , ... at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time), please ...
... Harry J. Guttman, Ph.D., J.D., will be giving opening, ... Event for Innovators and IP Professionals. This exciting ... other biotech industry service providers, and will be held ... Kingsgate Marriott Conference Hotel at the University of Cincinnati. ...
... ... the bacteria responsible. When treatment using other antibiotics has failed, Vancomycin is the strongest ... form which is effective against MRSA. , ... Westlake Village, CA (PRWEB) October 22, 2009 -- Sinus Dynamics™ ...
Cached Biology Technology:Sinus Dynamics Announced Treatment for MRSA with Nasal Nebulizer and Vancomycin 2
LAB/Probe Mouse-Rabbit DAB Kit...
Mouse monoclonal [SH-A1] to S100 alpha ( Abpromise for all tested applications). entrezGeneID: 6271 SwissProtID: P23297...
G-protein coupled purinergic receptor P2Y8...
This application changes sensitive keywords in an FCS file to remove patient information. It was contributed by Dr. David Miller....
Biology Products: